Efficacy and Adverse Events of Docetaxel for Metastatic, Hormone-sensitive Prostate Cancer Among Elderly Men: A Post Hoc Analysis of the CHAARTED Trial

被引：5

作者：

Li, Eric, V ^{[1
]}

Siddiqui, Mohammad R. ^{[1
]}

Weiner, Adam B. ^{[1
]}

Prizment, Anna E. ^{[2
]}

Ryan, Charles J. ^{[3
]}

Morgans, Alicia K. ^{[4
]}

机构：

[1] Northwestern Univ, Dept Urol, Feinberg Sch Med, Chicago, IL 60611 USA

[2] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA

[3] Univ Minnesota, Div Hematol Med Oncol & Transplantat, Minneapolis, MN USA

[4] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA

来源：

CLINICAL GENITOURINARY CANCER | 2021年 / 19卷 / 05期

关键词：

Geriatrics; Prostate cancer; Adverse events; OLDER; CASTRATION; MANAGEMENT; THERAPY;

D O I：

10.1016/j.clgc.2021.03.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This post hoc analysis of the CHAARTED trial compared efficacy/adverse events in different age groups for docetaxel/androgen deprivation therapy vs. androgen deprivation therapy alone. We found no significant difference in efficacy among age groups, but men 60, 60-70, and 60 years old). However, men age 70 years old experienced + 0.37 more adverse events per patient compared with men age < 60 years old (95% CI, 0.11-0.64; P = .006). Conclusions: PFS and OS were similar across age groups for the combination of docetaxel and ADT compared with ADT. Older men experienced a modest increase in adverse events per patient, highlighting the importance of balancing treatment benefits and adverse effects in this age group.

引用

页码：388 / 395

页数：8

共 17 条

[1] Efficacy and toxicity outcomes of elderly castrate-resistant prostate cancer patients treated with docetaxel-A pooled analysis of 3 randomized studies [J].

Abdel-Rahman, Omar .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (04) :210-215

[2] Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or ... [J].

Barata, Pedro C. ;

Sartor, A. Oliver .

CANCER, 2019, 125 (11) :1777-1788

[3] Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients [J].

Boyle, H. J. ;

Alibhai, S. ;

Decoster, L. ;

Efstathiou, E. ;

Fizazi, K. ;

Mottet, N. ;

Oudard, S. ;

Payne, H. ;

Prentice, M. ;

Puts, M. ;

Aapro, M. ;

Droz, J-P .

EUROPEAN JOURNAL OF CANCER, 2019, 116 :116-136

[4]

Clarke NW, 2019, ANN ONCOL, V30, P1992, DOI [10.1016/j.annonc.2020.01.002, 10.1093/annonc/mdz396]

[5]

Estimated cancer incidence mortality and prevalence worldwide in 2018., 2018, EST CANC INC MORT PR

[6] Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial [J].

Horgan, Anne M. ;

Seruga, Bostjan ;

Pond, Greg R. ;

Alibhai, Shabbir M. ;

Amir, Eitan ;

De Wit, Ronald ;

Eisenberger, Mario A. ;

Tannock, Ian F. .

JOURNAL OF GERIATRIC ONCOLOGY, 2014, 5 (02) :119-126

[7] Studies on prostate cancer II The effects of castration on advanced carcinoma of the prostate gland [J].

Huggins, C ;

Stevens, RE ;

Hodges, CV .

ARCHIVES OF SURGERY, 1941, 43 (02) :209-223

[8] Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer [J].

Italiano, Antoine ;

Ortholan, Cecile ;

Oudard, Stephane ;

Pouessel, Damien ;

Gravis, Gwenaelle ;

Beuzeboc, Philippe ;

Bompas, Emmanuelle ;

Flechon, Aude ;

Joly, Florence ;

Ferrero, Jean-Marc ;

Fizazi, Karim .

EUROPEAN UROLOGY, 2009, 55 (06) :1368-1376

[9] Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy [J].

James, N. D. ;

de Bono, J. S. ;

Spears, M. R. ;

Clarke, N. W. ;

Mason, M. D. ;

Dearnaley, D. P. ;

Ritchie, A. W. S. ;

Amos, C. L. ;

Gilson, C. ;

Jones, R. J. ;

Matheson, D. ;

Miliman, R. ;

Attard, G. ;

Chowdhury, S. ;

Cross, W. R. ;

Gillessen, S. ;

Parker, C. C. ;

Russell, J. M. ;

Berthold, D. R. ;

Brawley, C. ;

Adab, F. ;

Aung, S. ;

Birtle, A. J. ;

Bowen, J. ;

Brock, S. ;

Chakraborti, P. ;

Ferguson, C. ;

Gale, J. ;

Gray, E. ;

Hingorani, M. ;

Hoskin, P. J. ;

Lester, J. F. ;

Malik, Z. I. ;

McKinna, F. ;

McPhail, N. ;

Money-Kyrle, J. ;

O'Sullivan, J. ;

Parikh, O. ;

Protheroe, A. ;

Robinson, A. ;

Srihari, N. N. ;

Thomas, C. ;

Wagstaff, J. ;

Wylie, J. ;

Zarkar, A. ;

Parmar, M. K. B. ;

Sydes, M. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04) :338-351

[10] Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening [J].

Jemal, Ahmedin ;

Culp, MaryBeth B. ;

Ma, Jiemin ;

Islami, Farhad ;

Fedewa, Stacey A. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (01) :64-71

← 1 2 →